Name | 1-{3-[1-(3-Biphenylylmethyl)-1H-1,2,3-triazol-5-yl]phenyl}-3-(4-c hlorophenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine |
---|---|
Synonyms | KB SRC 4 |
Description | KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity. |
---|---|
Related Catalog | |
Target |
Ki: 44 nM (c-Src)[1] Kd: 86 nM (c-Src)[1] |
In Vitro | KB SRC 4 (Compound 4) is a potent, highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM. KB SRC 4 is selective between Src family members, with >2-fold selectivity over both Lck (Kd, 160 nM) and Fgr (Kd, 240 nM), 8-fold selectivity over c-Yes (Kd, 720 nM), and >40-fold selectivity over Lyn (Kd, 3200 nM), Hck (Kd, 4400 nM), and Fyn (Kd, >40000 nM). KB SRC 4 inhibits the growth of cancer cell lines, with GI50s of 11 μM, 12 μM, 11 μM, 6.0 μM against HT-29, SK-BR-3, MCF7, MDA-MB-453, and NIH-3T3, respectively[1]. |
References |
Molecular Formula | C32H23ClN8 |
---|---|
Molecular Weight | 555.03200 |
Exact Mass | 554.17300 |
PSA | 100.33000 |
LogP | 7.27310 |